title: High-density lipoprotein and progression rate of atherosclerosis in intravascular ultrasound trials.
abstract: Increasing interest has focused on the potential clinical utility of therapies that promote the biologic activity of high-density lipoprotein (HDL). Arterial wall imaging has been used in clinical trials to demonstrate that elevating HDL cholesterol has a beneficial impact on the natural history of the progression of atherosclerosis. As a result, it is likely that atherosclerosis imaging will become an integral component of early clinical development of novel therapies that enhance the functionality of HDL.
authors.affiliation: Departments of Cardiovascular Medicine and Cell Biology and the Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. nichols1@ccf.org
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Nicholls
mesh_terms: D001158:Arteries / Q000000981:diagnostic imaging*; D050197:Atherosclerosis / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000517:prevention & control*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy; D056128:Obesity, Abdominal / Q000188:drug therapy; D017539:Tunica Intima / Q000000981:diagnostic imaging; D017540:Tunica Media / Q000000981:diagnostic imaging; D018084:Ultrasonography, Interventional
chemical_list: D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors